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The effects of a and y interferons on human lung cancer
cells grown in vitro or as xenografts in nude mice
P.R. Twentyman, P. Workman, K.A. Wright & N.M. Bleehen
MRC Clinical Oncology and Radiotherapeutics Unit, Hills Road, Cambridge, UK.
Summary We have compared the effects of a and recombinant y interferons (IFNs) on the growth of human
lung cancer cell lines in vitro. There was a diversity of response amongst the lines studied, the most sensitive
being COR-L23 (a large cell anaplastic carcinoma line) and POC (a small cell line). In these two lines. IFN-y
was found to be more potent than IFN-a. During cell growth of line POC in the presence of IFN-y no
significant shift in cell cycle distribution occurred. When lines COR-L23 and POC were grown as xenograft
tumours in nude mice, daily injection of 4 x 105 units per mouse per day of IFN-y produced no discernible
retardation of tumour growth.
It is well established that interferons (IFNs) are
able to inhibit the growth of mammalian tumour
cells in vitro and also of xenografted tumours in
nude or immune-deprived mice (Pauker et al., 1962;
Taylor-Papadimitriou, 1980; Balkwill et al., 1982).
A number of different types of IFN have been used
in these experimental studies including human
leucocyte or lymphoblastoid (a) IFN, fibroblast (fi)
IFN and lymphocyte (immune) (y) IFN. Earlier
preparations of IFNs depended upon the
purification of very small amounts of material
obtained from cells grown in culture (Stewart,
1974), or from human blood (Cantell & Hirvonen,
1977). More recently IFN-a has been produced on
a large scale from bulk cell culture and
recombinant DNA techniques have allowed large
scale production of IFNs from cloned interferon
genes in E. coli bacteria. These cloned IFNs show
much higher degrees of purity than IFNs purified
from mammalian cell cultures.
Although IFN-c has been shown in clinical trials
to have some activity in lymphomas, breast cancer,
melanoma and myeloma, there was no response in
either non-small cell (Stoopler et al., 1980) or small
cell (Jones et al., 1983) lung cancers. In view of the
impending availability for clinical trial of
recombinant IFN-y, and our continuing interest in
lung cancer therapy, we decided to investigate the
comparative effects of IFN-a and IFN-y on lung
cancer cells in culture and the effect of IFN-y on
the growth of xenograft tumours in nude mice.
Materials and methods
Interferons
Human lymphoblastoid IFN-a was supplied by Dr
N. Finter (Wellcome). This highly purified IFN-oa
mixture is produced from the Namalwa cell line
of Burkitt lymphoma. Its sp. act. was
1.0 x 108 IUmg-I protein (prior to the addition of
human serum albumin as stabiliser). Recombinant
IFN-y was kindly supplied by Biogen S.A.
(Geneva). Two batches were used with sp. act. of
2.6 and 3.75 x 107 IUmg-1 protein respectively.
IFNs were stored at -70°C in storage buffer
containing human serum albumin. Diluted aliquots
in PBS were also stored at -70°C and thawed
immediately before addition to cell cultures or
injection into mice. The only exceptions to this were
for some experiments (stated in Results) where IFN
solutions for daily administration were kept at 4°C
for the duration of the experiment.
Cell lines and media
A number of cell lines were initially studied in
order to gain information on the range of responses
to a given dose of the two types of IFN. BEN,
MOR and POC are human squamous cell, adeno
and small cell lung cancer lines respectively and
were supplied by Dr M. Ellison, Ludwig Institute,
Sutton; NCI-H69 is a human small cell lung cancer
line supplied by Dr D. Carney, NCI-Navy Medical
Oncology Branch; EMT6/Ca/VJAC and RIF-l are
mouse mammary tumour and mouse sarcoma cell
lines respectively; COR-L23 is a cell line derived
from the pleural fluid of a patient with large cell
lung cancer and which forms tumours in nude mice.
The mode of growth and the media used for each
line are shown in Table I. All culture media and
serum were supplied by Gibco Ltd. HITES medium
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Table I Cell lines and growth conditions.
Cell line Origin Mode ofgrowth Medium
BEN human attached monolayer RPMI 1640
squamous cell lung + 10% FCS
MOR human attached monolayer RPMI 1640
adenocarcinoma + 10% FCS
lung
POC human floating aggregates RPMI 1640
small cell lung + 10% FCS
NCI-H69 human floating aggregates RPMI 1640
small cell lung + 10% FCS
COR-L23 human attached monolayer HITES
large cell lung +2.5% FCS
EMT6/Ca/VJAC mouse attached monolayer Eagles MEM
mammary tumour +20% NBCS
RIF-l mouse attached monolayer Eagles MEM
sarcoma +20% NBCS
consisted of RPMI 1640 supplemented with
hydrocortisone, insulin, transferrin, oestradiol and
selenium as described by Carney et al. (1981).
Cell growth experiments
Cells were grown in the appropriate medium in
25CM2 tissue culture flasks (Falcon). Some of the
cell lines grew as attached monolayers whilst others
grew as floating aggregates (see Table I). The
required number of flasks was set up from a large
single cell suspension and IFN added as
appropriate. At various times afterwards, the
growth medium was removed from the cells in a
flask (monolayers) or after centrifugation of the
contents of a flask transferred to a plastic
centrifuge tube (floating aggregates). A solution of
0.4% trypsin and 0.2% versene in PBS was then
used to prepare a single cell suspension by
incubation at 37°C for 15min, and phase-contrast
viable cells were counted using a haemocytometer.
In some experiments, the growth medium was
changed daily and fresh IFN added.
Multicellular tumour spheroids
Both POC and COR-L23 can be grown as
multicellular tumour ,spheroids under static
conditions. Spheroids of POC were initiated by the
inoculation of 106 cells into 75cm2 tissue culture
flasks. Aggregation occurred rapidly and spheroids
of 250pm diameter were present by day 14. As
COR-L23 cells normally grow in monolayer, it was
necessary to base-coat 75cm2 flasks with I% Difco
noble agar in medium to prevent cell attachment
(Twentyman, 1980). Spheroids of 250p,m diameter
were obtained by day 10 following inoculation of
5 x 105 cells per flask.
When the spheroids had reached a diameter of
250-400im, they were individually transferred to
wells on 24 well tissue culture trays (Linbro) using
a Pasteur pipette. Medium (1 ml) was added to each
well and spheroids were then measured three times
weekly using an inverted microscope and an image
analysis system (Twentyman, 1982). In some
experiments, the effect of carrying out a daily
medium change was studied.
Flow cytometry
After preparation of a single cell suspension as
above, cells were suspended at 2 x I0O cellml - in
RPMI 1640 medium containing 10% foetal calf
serum. Staining with a mixture of mithramycin and
ethidium bromide was carried out (Taylor, 1980)
and the fluorescence distribution measured by
passing the cells through the Cambridge flow
cytometer using an argon laser operating at 488um
(Watson, 1980). Analysis of cell cycle distribution
was carried out using the method of Watson et al.
(1985).
Mouse experiments
Nude mice (MF1 nunu) were obtained from OLAC
Ltd. and maintained in negative pressure isolators
(Vickers Medical) before and during experiments.
They were used in experiments at a weight of
20-30g. Solid tumours were grown by injecting
2-5 x 106 cells into the gastrocnemius muscle of the
hind limb. Cells were obtained from a previous
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or more tumours and preparation of a single cell
suspension using 1 mgml-1 bacterial neutral
protease (Sigma, Type IX). The experiments
described in this paper were all carried out using
xenograft-passage 2-4 from the in vitro cell line.
Tumour growth was assessed by measuring two leg
diameters at right angles using a perspex gauge in
association with a calibration curve of leg diameter
versus tumour weight (Twentyman et al., 1979).
IFN-y administration was commenced when
individual tumours reached 200-300mg and
tumours were then measured twice weekly as was
mouse body weight. The time for each individual
tumour to attain 4 x its weight at the onset of
treatment was then assessed. IFN-y was
administered either by the i.p. or the s.c. route at a
dose of 4 x 10 5 IU per mouse per day in a volume
of 0.1 ml per mouse per day. It was diluted to the
appropriate concentration in storage buffer or
saline, aliquoted and refrozen prior to use. In some
experiments, aliquots were thawed immediately
before administration. In others, sufficient IFN for
2-3 days treatment was thawed and stored at 4°C.
Appropriate solvent controls were included in all
experiments.
Results
Effects ofIFNs on cell growth
In a series of initial experiments, the effect of IFN-
a and IFN-y at a dose of 103IUml-I on the
growth of various cell types was studied. The data
are shown in Table II. It may be seen that both
types of IFN had some effect on the growth of the
human cells, but there was no clear effect on the
mouse cells (EMT6/Ca/VJAC and RIF-1). Among
the human cells, POC and COR-L23 were the most
sensitive (especially to IFN-y) whereas NCI-H69
was relatively resistant. Growth curves for POC
and NCI-H69 in the presence of 103IUml-1 of
IFN-a or IFN-y are shown in Figure 1. These data
confirm the relative sensitivity of POC compared
with NCI-H69 and also the greater effect of IFN-y
compared with IFN-a. Growth curves (not shown)
for COR-L23 confirmed this latter point. We also
obtained dose-response data for IFN-a and for our
2 batches of IFN-y on POC and COR-L23. Data
for COR-L23 are shown in Figure 2. It may be
seen that the 2 batches of IFN-y were of similar
potency and the IFN-oa was less effective. A similar
conclusion was drawn from the data for POC (not
shown). On the basis of these data it was decided to
concentrate attention in subsequent experiments
upon the effects of IFN-y on POC and COR-L23.
More complete dose-response data for the effect
of IFN-y on these cells are shown in Figure 3. The
curves for both cell lines fall rapidly between 0 and
500IUml-1 of IFN-y with little further effect with
increasing dose.
We also carried out experiments to study the
effect on cell growth of IFN-y replenished daily
versus a single addition at the onset of the
experiments. The data are shown in Table III. In
Table II Effect ofIFN-a and IFN-y on the growth ofcell lines.
Exp. I Exp. 2
cells/flask (x 10S) cells/flask (x 10S)
CONT IFN-ot IFN-y CONT IFN-a IFN-y
BEN 6.8 5.2 3.6 10.4 12.0 8.0
MOR 4.4 2.6 3.3 8.2 4.6 4.9
POC 4.6 2.5 1.4 7.8 4.2 3.7
NCI-H69 6.1 4.2 4.9 4.0 3.8 3.1
COR-L23 3.7 2.4 0.9 7.4 5.1 1.6
EMT6/Ca/VJAC 24.5 25.3 28.3 37.0 35.0 42.0
RIF-1 24.5 22.0 24.4 11.2 9.7 8.2
Notes:
(a) Figures are counts ofphase-contrast viable cells from single flasks.
(b) IFNs added at 103 IUml-1 on day 0 and unchanged throughout.
(c) Experiment 1 - all flasks set up at 105 cells on day 0
Final counts: EMT6/Ca/VJAC; RIF-I - day 3
NCI-H69; BEN; MOR; COR-L23 - day 6
POC - day 8.
(d) Experiment 2 - all flasks set up at 105 cells on day 0 except NCI-
H69=2 x 105 cells on day 0.
Final counts: EMT6/Ca/VJAC; RIF-l - day 3
NCI-H69 - day 6
BEN; MOR; COR-L23 - day 8
POC - day 9.
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Figure 2 Effect of different doses of IFN-a (-) or
two different batches of IFN-y (A, A) on the growth
of COR-L23 cells. Flasks were inoculated with 105 cells
on day 0 and IFN added immediately. Cells/flask were
counted on day 9.
(a) and POC cells (b) of IFN-a or IFN-y added at
both POC experiments there was a greater effect of
IFN-y when replenished daily. For COR-L23,
however, there did not appear to be a great
difference between the effects of the two regimes.
A recent report (Bakhanashvili et al., 1983) has
shown that cells can be more sensitive to the
inhibitory effects of IFN when grown in low serum
concentrations. In order to test whether the high
sensitivity of COR-L23 was due to the fact that we
grow this line in 2.5% serum rather than the 10%
used for the other lines, we carried out a
comparative study using high and low serum
concentrations. The results are shown in Table IV.
It may be seen that the effect of IFN-y on COR-
L23 was not dependent upon the medium used.
Flow cytometry studies
As the cells in COR-L23 have an extremely hetero-
geneous distribution of DNA content per nucleus,
we used line POC to examine the effect of IFN-y
on cell cycle distribution. The data from 2 such
experiments are shown in Table V. In the first
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Table III Comparison of the effects of a single addition of IFN-y to growth medium
versus daily renewal of IFN-y.
Dose ofIFN-y Cells/flask (x 105)
Experiment Cell line IUml-1 single IFN-y daily IFN-y Note
I POC 0 14.8 12.7 1
103 4.8 1.7
2 POC 0 18.0 20.2 2
200 17.5 10.9
103 12.0 10.2
3 COR-L23 0 6.0 8.3 3
103 3.6 3.7
4 COR-L23 0 14.0 11.0 4
103 5.8 6.3
1. Set up at 3 x 105/flask, counted at day 7.
2. Set up at 2 x 105/flask, counted at day 8.
3. Set up at 105/flask, counted at day 6.
4. Set up at 105/flask, counted at day 6.
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Figure 3 Effect of different doses of IFN-y on the
growth of POC (0) and COR-L23 (0) cells. For POC
the flasks were inoculated with 2 x 101 cells on day 0
and counted on day 9. For COR-L23 cells, the flasks
were inoculated with 105 cells on day 0 and counted
on day 7. IFN was added to flasks immediately after
the cells.
experiment (A) IFN-y was added to the flasks
immediately after the cells on day 0. In experiment
B, flasks were inoculated on day 0 but then allowed
to grow for 3 days before addition of the IFN to
ensure that the results were not influenced by the
disaggregation procedure. In each experiment an
Table IV Effect of IFN-y on the growth of COR-L23 in
two different growth media.
IFN-y dose Cells/flask
Medium IUml-1 (X 105)
HITES+2.5% FCS 0 9.9
500 7.2
2x 103 3.4
RPMI+10% FCS 0 9.5
500 6.9
2x103 2.9
Flasks set up at 105 cells on day 0, counted on day 6.
effect of the IFN-y on cell growth was observed but
there was no clear effect upon cell cycle
distribution.
Effect upon spheroidgrowth
In order to compare the effects of IFN-y on cells in
suspension with that on multicellular tumour
spheroids we carried out the following procedure.
Cells of the POC line were inoculated into flasks
and allowed to grow into spheroids of 200-400 m
diameter (as described in Materials and methods). At
this time, some of the spheroids were disaggregated
and flasks inoculated with 2 x 105 cells per flask. In
addition, individual spheroids were placed into
single wells on 24 well multidishes and measured
daily. IFN-y (103IUm -1) was added to flasks or
wells at the onset of this experiment and either left
throughout the experiment or changed daily. The
results of these experiments are shown in Table VI.
In experiment A there was a relatively small effect
on the cells growing in flasks when the IFN-y was
left unchanged and this regime had no effect on
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Table V Effect of IFN-y on cell growth and cell cycle
distribution of POC cells.
% ofcells in
IFN-y Cells/flask
Exp. Day IUml-1 x 105 GI S G2
Aa 0 10.0 52.8 38.2 9.0
2 0 12.6 47.9 40.1 12.0
103 8.8 46.8 36.5 16.7
3 0 19.6 50.0 41.4 8.6
103 12.4 49.0 36.4 14.5
6 0 38.8 54.7 37.3 8.1
103 26.4 53.3 36.9 9.8
Bb 0 10.0 44.3 42.9 12.7
4 0 15.8 44.1 44.9 11.0
103 14.5 41.5 42.9 15.6
5 x 103 14.2 43.7 42.9 13.3
5 0 27.6
103 22.6
5x 103 22.2
6 0 31.0 49.0 36.1 14.9
103 24.5 49.1 38.5 12.3
5 x 103 24.4 48.8 34.2 17.0
'In experiment A, flasks were inoculated with 106
cells/flask on day 0 and IFN-y was added at the same
time.
bIn experiment B, flasks were inoculated with Sx 101
cells/flask on day 0, IFN-y was added on day 3.
Table VI Effect ofIFN-y on spheroid growth compared with cell multiplication in POC cells.
Daily IFN-y Cells/flask Mean spheroid Mean spheroid Increase in
medium dose at day 7 diameter diameter diameter
Exp. change IU/mi (x 106)a day O(UM)b day 7(pm) (jm)
A NO 0 2.21 445 735 290
NO 103 1.69 430 740 310
YES 0 1.25 425 730 305
YES 103 0.62 430 690 260
B NO 0 1.56 330 710 380
NO 103 1.75 315 735 420
YES 0 0.95 240 635 385
YES 103 0.70 315 630 315
C NO 0 1.68 448(31) 885(28) 437(41)
NO 103 1.02 383(21) 763(62) 383(65)
YES 0 1.16 439(32) 801(26) 362(41)
YES 103 0.49 418(26) 768(41) 350(49)
a2 flasks per point - values given are mean counts.
b8-12 spheroids per treatment group.
In experiments A and B, data on individual spheroid diameters were not stored and hence s.e.
not given.
In experiment C, figures in parentheses indicate 2 s.e. ofthe mean.EFFECTS OF IFNS ON HUMAN LUNG CANCER CELLS
Table VII Effect of IFN-y on growth on human cell lines as
tumours in nude mice.
Time to reach 4 x treatment
size (days)
Route of Buffer IFN-y IFN-y
Exp. Cell line IFN admina control Batch 2 Batch I
A POC i.p. 7.6 7.3
(6.8-8.2) (6.2-8.5)
n=15 n=14
B NCI-H69 i.p. 9.1 9.4
(7.8-10.6) (7.6-11.8)
n=6 n=6
C COR-L23 s.c. 8.2 8.3
(6.4-10.6) (7.1-9.7)
n=7 n=6
D COR-L23 s.c. 6.9 6.8 6.3
(5.9-8.1) (5.5-8.2) (5.2-7.6)
n=6 n=6 n=6
aDose=4 x 105 i.u. per mouse per day (equivalent to
1.6 x 107IUkg-1day-' or 4.8 x 107IUm-2day-').
Values of time in days are geometric means of groups of n mice
with 2s.e. limits in parentheses.
spheroid growth. A larger effect was seen in flasks
with daily medium change and a small inhibition of
spheroid growth was also observed. In experiment
B, a single administration of IFN-y produced no
inhibition (in fact a small increase) in cells per flask
and also in spheroid growth. Again the daily
medium change regime was rather more effective in
both systems. In experiment C, results in flasks are
similar to those of experiment A, whereas spheroid
growth was suppressed more for single than for
repeated administration of IFN. The two standard
error limits on mean spheroid diameter values in
experiment C, however, indicate that the differences
are not statistically significant and the same almost
certainly applies to the equivalent data for
experiments A and B. It would appear, therefore,
that major differences seen in cells per flask
(experiments A and C) for repeated administration
of IFN-y do not result in equally large suppression
of spheroid growth. This may indicate a reduced
sensitivity of cells in large 3-dimensional aggregates
or a failure of IFN to penetrate into the spheroids.
Effect in vivo
The data from 4 experiments carried out using
human lung cell lines grown as tumours in nude
mice are shown in Table VI. There was no
significant effect of IFN-y in any of the
experiments. No weight loss was seen in any of the
groups of mice, neither were there any other visible
signs of toxicity with the exception of one death
due to haematoma at the site of s.c. injection.
Discussion
The results presented in this paper indicate that
both IFN-ax and IFN-y are able to cause a partial
suppression of the growth of some human lung
cancer cell lines. In a direct comparison at a dose
of 103IU ml-1, the effect of IFN-y was generally
greater than that of IFN-a on the two most
sensitive lines (POC and COR-L23) and this
comparison was confirmed over a wide range of
doses. The effect of IFN-y was related to dose over
the region -104i.u.ml-P but the major part of the
effect occurred below a dose of 500IUml-'. The
major effect of IFN-y on cell growth curves was
greatest at early times with later growth becoming
almost parallel to control. These data on cell
sensitivity to IFN-a and IFN-y may be compared
with data from the literature for the effect of IFN-a
on other cell lines (reviewed by Stewart, 1979). The
Daudi line of human lymphoblastoid cells is
particularly sensitive (Adams et al., 1975; Gewart et
al., 1981) (i.e. effects seen at less than
10IUml-1) whereas others are resistant to several
thousand units. Our lines POC and COR-L23
may therefore be regarded as of intermediate
sensitivity whereas the lines showing little or no
response to 103IUmI- may be regarded as
resistant.
Our flow cytometry studies did not reveal any
major perturbations in the cell cycle distribution of
cells growing in the presence of IFN-y. Although
some workers have found that IFNs do not cause
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major perturbations in cell cycle distribution
(Killander et al., 1976; Balkwill et al., 1978), a very
wide diversity of effects of IFNs on cell cycle
kinetics and phase distribution have, however, been
reported by others (Watenabe et al., 1978;
Lundgren et al., 1979; Creasey et al., 1980;
Lundblad & Lundgren, 1981; Roos et al., 1984). In
the study by Lundblad and Lundgren (1981) the
effects of IFN-oa and IFN-f on a glioma cell line in
exponential growth were studied using flow
cytometry. The proportion of cells with DNA
contents corresponding to the S phase of the cell
cycle was markedly increased in IFN treated cells.
The authors combined their flow cytometry data
with data obtained using labelling techniques to
conclude that IFN was causing cessation of DNA
synthesis before normal replication was complete. A
number of human haemopoietic cell lines and fresh
leukaemic cells were studied by Roos et al. (1984).
They found that the main effect of IFN-cx was to
cause a block in the Go-G1 phase of the cell cycle,
although the Burkitt's lymphoma line, Namalwa,
showed decreased progress through S without any
Go/GI accumulation, thereby leading to an
increased S phase fraction judged by flow
cytometry. Our flow cytometry data are difficult to
interpret in detail in the absence of labelling studies
to measure the rate of DNA synthesis. Clearly,
however, major perturbations in cell cycle
distribution which have been reported by others do
not occur in the POC cell line treated with IFN-y.
The growth inhibiting effects occurring at the time
when flow cytometry was performed must therefore
be dependent upon change in the rate of progress
of cells around the cycle rather than major blocking
at a specific point.
The negative results for the effect of 4 x 105i.u.
day-l of IFN-y on tumours growing in nude mice
are disappointing. It has been shown by Balkwill et
al. (1982) that IFN-ax is able to slow the growth of
a human breast carcinoma xenograft if given in
daily doses of 2 x 105IU to nude mice. The same
total weekly dose (i.e. 1.4 x 106 IU) either as a
single dose or as 3 doses per week was much less
effective. These doses were chosen as being
approximately equivalent to the doses (based on
IUm-2) which are achievable in man. A similar
dose regime for IFN-a was used by Clutterbuck et
al. (1983) to treat immune-deprived mice bearing
xenografts of human lung adenocarcinoma,
melanoma or acute myeloid leukaemia. In these
experiments, IFN administration was carried out
daily from the day before tumour implant for 14
days. No effect was seen on the growth of any of
the tumours. The conclusion reached by Balkwill et
al. (1982) from their data was that the positive
response observed was likely to be due to a direct
effect on the human cells rather than a host effect
upon the nude mice used. If this is so, it appears
that the psotive response to IFN-y which we have
observed for COR-L23 and POC cells in vitro does
not directly predict for a similar response in
xenografted tumours. It may be, however, that this
negative result is due to pharmacokinetic reasons.
No detectable anti-viral activity was detected in
patients' serum following i.m. injection of partially
pure IFN-y and non-glycosylated recombinant IFN-
y appeared to be poorly absorbed in the squirrel
monkey after i.m. administration (Gutterman et al.,
1984). We were unable, however, to carry out
repeated i.v. injections into nude mice and thus are
unable to directly compare routes of
administration.
It is far from clear to what extent clinical
response to IFNs is dependent upon direct
cytotoxicity or cytostasis in the tumour cell
population. In addition, a detailed knowledge of
the pharmacokinetics of IFN-y in both the mouse
and in man will be necessary for a direct
comparison of in vitro, in vivo and clinical results.
The implications of our data for the likely effect of
IFN-y in clinical trials of lung cancer therapy must
therefore remain uncertain.
We thank Mr S. Chambers and Dr J.V. Watson for
carrying out flow cytometric analysis of treated
populations ofcells and Mrs Jane Donaldson for her help
with xenograft experiments.
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